<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32125773</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1582-4934</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of cellular and molecular medicine</Title><ISOAbbreviation>J Cell Mol Med</ISOAbbreviation></Journal><ArticleTitle>Reprogramming fibroblasts and peripheral blood cells from a C9ORF72 patient: A proof-of-principle study.</ArticleTitle><Pagination><StartPage>4051</StartPage><EndPage>4060</EndPage><MedlinePgn>4051-4060</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.15048</ELocationID><Abstract><AbstractText>As for the majority of neurodegenerative diseases, pathological mechanisms of amyotrophic lateral sclerosis (ALS) have been challenging to study due to the difficult access to alive patients' cells. Induced pluripotent stem cells (iPSCs) offer a useful in vitro system for modelling human diseases. iPSCs can be theoretically obtained by reprogramming any somatic tissue although fibroblasts (FB) remain the most used cells. However, reprogramming peripheral blood cells (PB) may offer significant advantages. In order to investigate whether the choice of starting cells may affect reprogramming and motor neuron (MNs) differentiation potential, we used both FB and PB from a same C9ORF72-mutated ALS patient to obtain iPSCs and compared several hallmarks of the pathology. We found that both iPSCs and MNs derived from the two tissues showed identical properties and features and can therefore be used interchangeably, giving the opportunity to easily obtain iPSCs from a more manageable source of cells, such as PB.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bardelli</LastName><ForeName>Donatella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sassone</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombrita</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpe</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gumina</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peverelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catusi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Lab. di Citogenetica Medica, IRCCS Istituto Auxologico Italiano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratti</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dino Ferrari" Center, Department of Pathophysiology and Transplantation, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossolasco</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1596-7818</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cell Mol Med</MedlineTA><NlmUniqueID>101083777</NlmUniqueID><ISSNLinking>1582-1838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001773" MajorTopicYN="N">Blood Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065150" MajorTopicYN="N">Cellular Reprogramming</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">
C9ORF72
</Keyword><Keyword MajorTopicYN="N">RNA foci</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">fibroblasts</Keyword><Keyword MajorTopicYN="N">iPSCs</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">peripheral blood cells</Keyword><Keyword MajorTopicYN="N">repeat expansion</Keyword><Keyword MajorTopicYN="N">reprogramming</Keyword></KeywordList><CoiStatement>The authors confirm that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32125773</ArticleId><ArticleId IdType="pmc">PMC7171411</ArticleId><ArticleId IdType="doi">10.1111/jcmm.15048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH. Amyotrophic lateral sclerosis: Insights from genetics. Arch Neurol. 1997;54:1246&#x2010;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341570</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, et al. TDP&#x2010;43 is a component of ubiquitin&#x2010;positive tau&#x2010;negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2010;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;107:861&#x2010;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenaka C, Nishishita N, Takada N, Jakt LM, Kawamata S. Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. Exp Hematol. 2010;38:154&#x2010;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922768</ArticleId></ArticleIdList></Reference><Reference><Citation>Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol. 2008;26:1276&#x2010;1284.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931654</ArticleId></ArticleIdList></Reference><Reference><Citation>Staerk J, Dawlaty MM, Gao Q, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7:20&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917234</ArticleId><ArticleId IdType="pubmed">20621045</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh Y&#x2010;H, Hartung O, Li HU, et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010;7:15&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913590</ArticleId><ArticleId IdType="pubmed">20621044</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I&#x2010;H, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">18157115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA. 2008;105:2883&#x2010;2888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268554</ArticleId><ArticleId IdType="pubmed">18287077</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain SJ, Li XJ, Lalande M. Induced pluripotent stem (iPS) cells as in vitro models of human neurogenetic disorders. Neurogenetics. 2008;9:227&#x2010;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">18791750</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene&#x2010;free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Japan Acad Ser B Phys Biol Sci. 2009;85:348&#x2010;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3621571</ArticleId><ArticleId IdType="pubmed">19838014</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie I, Boeve B, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;Linked FTD and ALS. Neuron. 2011;72:245&#x2010;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossolasco P, Sassone F, Gumina V, Peverelli S, Garzo M, Silani V. Motor neuron differentiation of iPSCs obtained from peripheral blood of a mutant TARDBP ALS patient. Stem Cell Res. 2018;30:61&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">29800782</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukusumi H, Shofuda T, Bamba Y, et al. Establishment of human neural progenitor cells from human induced pluripotent stem cells with diverse tissue origins. Stem Cells Int. 2016;2016:1&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861799</ArticleId><ArticleId IdType="pubmed">27212953</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron. 2011;72:257&#x2010;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross&#x2010;sectional study. Lancet Neurol. 2012;11:323&#x2010;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuva&#x2010;Aydemir Y, Almeida S, Gao FB. Insights into C9ORF72&#x2010;related ALS/FTD from drosophila and iPSC Models. Trends Neurosci. 2018;41:457&#x2010;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015541</ArticleId><ArticleId IdType="pubmed">29729808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P, Bieniek K, Gendron T, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2010;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2010;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, Gascon E, Tran H, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC&#x2010;derived human neurons. Acta Neuropathol. 2013;126:385&#x2010;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C, Zhang P&#x2010;W, Pham J, et al. RNA Toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2010;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non&#x2010;neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2014;24:3133&#x2010;3142.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki J, Nakamori M, Nakamura M, et al. Myotonic dystrophy type 1 patient&#x2010;derived iPSCs for the investigation of CTG repeat instability. Sci Rep. 2017;7:42522</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304155</ArticleId><ArticleId IdType="pubmed">28211918</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt MF, Martinez FJ, Wright S, et al. A cellular model for sporadic ALS using patient&#x2010;derived induced pluripotent stem cells. Mol Cell Neurosci. 2013;56:355&#x2010;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B, Serio A, Barmada SJ, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP&#x2010;43 proteinopathies and reveal cell&#x2010;specific vulnerability. Proc Natl Acad Sci. 2012;109:5803&#x2010;5808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient&#x2010;specific induced pluripotent stem cells. Sci Transl Med. 2012;4(145):145ra104</Citation><ArticleIdList><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Seminary ER, Sison SL, Ebert AD. Modeling protein aggregation and the heat shock response in ALS iPSC&#x2010;derived motor neurons. Front Neurosci. 2018;12:86</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5826239</ArticleId><ArticleId IdType="pubmed">29515358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang KE, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2010;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>